Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1537310 | 0.92 | CYP3A4 (0.58) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL244229 | 0.92 | CYP3A4 (0.58) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL8373019 | 0.90 | CYP3A4 (0.60) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL163444 | 0.90 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL1537285 | 0.90 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL5652907 | 0.89 | CYP3A4 (0.58) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL3457999 | 0.89 | CYP3A4 (0.61) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28331180 | 0.89 | CYP3A4 (0.69) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL183770 | 0.88 | CYP3A4 (0.55) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL9082370 | 0.87 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793932-B1 | CTP-BASED INSULIN ANALOGS FOR TREATMENT OF DIABETES | UNIV INDIANA RES & TECH CORP (US) | 2018-10-03 | — | — | EP | claimed |
| US-20160184271-A1 | Amino Acid Composition for Use in the Treatment of a PDD | N. V. NUTRICIA (NL) | 2016-06-30 | — | — | US | disclosed |
| EP-3016647-A1 | AMINO ACID COMPOSITION FOR USE IN THE TREATMENT OF A PDD | N.V. Nutricia (NL) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015002527-A1 | AMINO ACID COMPOSITION FOR USE IN THE TREATMENT OF A PDD | N.V. NUTRICIA (NL) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015002537-A1 | AMINO ACID COMPOSITION FOR USE IN THE TREATMENT OF A PDD | N.V. NUTRICIA (NL) | 2015-01-08 | — | — | WO | disclosed |
| US-20050192460-A1 | Process for preparing amino acid esters and their acid addition salts | GOLDSCHMIDT GMBH (DE) | 2005-09-01 | — | — | US | disclosed |
| EP-1150709-A2 | ANTI-MICROBIAL AGENTS, DIAGNOSTIC REAGENTS, AND VACCINES BASED ON APICOMPLEXAN PARASITE COMPONENTS | Mcleod, Rima W. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000066154-A2 | ANTI-MICROBIAL AGENTS, DIAGNOSTIC REAGENTS, AND VACCINES BASED ON UNIQUE APICOMPLEXAN PARASITE COMPONENTS | ARCH DEVELOPMENT CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-0546108-A4 | PRO-DRUGS FOR CCK ANTAGONISTS | — | 1993-09-22 | — | — | EP | disclosed |
| EP-0546108-A1 | PRO-DRUGS FOR CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1993-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192460-A1 | Process for preparing amino acid esters and their acid addition salts | BCAT1, BCAT2, MAX | CYP3A4 1066/4885SLC7A5 40/4885HRH4 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.